Daiken Medical Co (TSE:7775) EBITDA: 円1,516 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7775 Daiken Medical Co Ltd TSE:7775
62 GF Score
Price 円426.00
GF Value 円541.84
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Daiken Medical Co EBITDA?

Daiken Medical Co TSE:7775 +0.24% 62 EBITDA is 円1,516 Mil as of Mar. 2026. GuruFocus rates TSE:7775 with a GF Score™ of 62/100 and a GF Value™ of 円541.84 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Daiken Medical Co's EBITDA for the six months ended in Mar. 2026 was 円712 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,516 Mil.

During the past 12 months, the average EBITDA Growth Rate of Daiken Medical Co was -13.40% per year. During the past 3 years, the average EBITDA Growth Rate was 5.40% per year. During the past 5 years, the average EBITDA Growth Rate was 5.60% per year. During the past 10 years, the average EBITDA Growth Rate was -1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Daiken Medical Co was 21.60% per year. The lowest was -9.40% per year. And the median was 6.00% per year.

Daiken Medical Co's EBITDA per Share for the six months ended in Mar. 2026 was 円24.77. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2026 was 円52.79.

During the past 12 months, the average EBITDA per Share Growth Rate of Daiken Medical Co was -13.40% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 5.40% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 5.60% per year. During the past 10 years, the average EBITDA per Share Growth Rate was -0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Daiken Medical Co was 12.10% per year. The lowest was -15.20% per year. And the median was 5.70% per year.

Daiken Medical Co  (TSE:7775) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Daiken Medical Co EBITDA Related Terms


Daiken Medical Co EBITDA Historical Data

* Premium members only.

The historical data trend for Daiken Medical Co's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiken Medical Co EBITDA Chart

Daiken Medical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,469.50 1,296.29 1,655.56 1,750.39 1,516.49

Daiken Medical Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 798.81 953.32 797.06 804.94 711.55

TSE:7775 vs ISRG, BDX, MDLN: EBITDA Comparison

For the Medical Instruments & Supplies subindustry, Daiken Medical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiken Medical Co EV-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Daiken Medical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Daiken Medical Co's EV-to-EBITDA falls into.


TSE:7775
62GF Score
Daiken Medical Co Ltd TSE:7775
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Daiken Medical Co's EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Daiken Medical Co's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Mar. 2026, Daiken Medical Co's EBITDA was 円1,516 Mil.

Daiken Medical Co's EBITDA for the quarter that ended in Mar. 2026 is calculated as

Daiken Medical Co's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2026, Daiken Medical Co's EBITDA was 円712 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円1,516 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of 円1,516 Mil mean?
Daiken Medical Co (TSE:7775) has a EBITDA of 円1,516 Mil as of Mar. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Daiken Medical Co.
Is Daiken Medical Co's EBITDA too high?
Daiken Medical Co's current EBITDA is 円1,516 Mil. Overall, Daiken Medical Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiken Medical Co's EBITDA compare to ISRG and BDX?
Daiken Medical Co's EBITDA of 円1,516 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Devices & Instruments company?
A good EBITDA depends on the Medical Devices & Instruments industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Daiken Medical Co. Daiken Medical Co's current EBITDA is 円1,516 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Daiken Medical Co (TSE:7775) is currently considered Modestly Undervalued. The stock's GF Value™ is 円541.84, compared to a current price of 円426.00 — trading 21.4% below its estimated fair value. The current EBITDA is 円1,516 Mil. Daiken Medical Co's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Daiken Medical Co (TSE:7775), the current EBITDA is 円1,516 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daiken Medical Co (TSE:7775) Overvalued in 2026?

Based on GuruFocus' analysis, Daiken Medical Co stock appears to be undervalued. The current stock price of 円426.00 is trading 21.4% below its estimated GF Value™ of 円541.84. GuruFocus considers Daiken Medical Co to be Modestly Undervalued.

Key valuation signals for TSE:7775:

  • EBITDA: 円1,516 Mil
  • GF Value™: 円541.84 vs. price of 円426.00 (21.4% below fair value)
  • GF Score™: 62/100 with 1 warning sign

No single metric tells the full story. See the TSE:7775 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Daiken Medical Co Business Description

Address 3-6-1, Dosho-Machi, Chuo-Ku, Osaka, JPN, 541-0045
Daiken Medical Co Ltd manufactures and sells medical equipment. The product line includes - Coopdech syrinjector, Coopdech Syrinjector PCA device, Coopdech Balloonjector, Coopdech Endobronchial blocker tube, Coopdech double-lumen endobronchial tube, Fit fix suction container system, Wet disinfectant mat, and others.
62GF Score

Get the complete analysis for TSE:7775

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円426.00
Price
円541.84
GF Value